What a RIM System Needs for Biologics and Advanced Therapies

What does an end-to-end RIM system need to support biologics and advanced therapies? At minimum: a single system of record for regulatory documents and submissions that can absorb complex, multi-region programs — INDs, BLAs, CTAs, and accelerated pathways — without forcing a team onto spreadsheets or a second tool for correspondence tracking. For cell and gene therapy and other advanced-therapy programs specifically, that also means handling higher submission complexity and more frequent agency interaction than a typical small-molecule program, without adding headcount just to keep the system fed.

Why biologics and advanced therapies strain a generic RIM setup

Biologics and advanced therapy programs generate more regulatory surface area per asset than most small-molecule programs. As of September 2026, the FDA has approved 51 cellular and gene therapy products [1], and the EMA has authorised 33 active advanced therapy medicinal products (ATMPs) [2] — a small but fast-growing category that regulators are still actively building guidance around. That means more frequent agency correspondence, more amendments as guidance evolves mid-program, and more scrutiny on chain-of-custody for manufacturing and clinical documentation.

A RIM system built for a generic small-molecule submission cadence tends to break down here in a few specific ways: correspondence volume outgrows a shared inbox or tracker, document relationships between CMC, nonclinical, and clinical modules become hard to trace across a spreadsheet, and version control across the multiple resubmissions common to advanced-therapy review cycles gets error-prone. None of this is unique to any one vendor — it's a function of the therapy category, not a flaw in any single RIM product — but it does raise the bar for what "end-to-end" needs to mean.

What "end-to-end" actually means for a RIM system

"End-to-end" gets used loosely in RIM marketing, so it's worth being specific. For a biologics or advanced-therapy program, it should cover the full lifecycle from early document authoring through post-approval maintenance, in one system:

• Authoring and document control — the underlying documents (protocols, CMC sections, nonclinical study reports, correspondence) live in a controlled, audit-trailed system rather than being authored elsewhere and uploaded as a final step.
• Submission planning and assembly — pre-built or configurable submission structures aligned to agency guidance (IND, BLA, CTA, and equivalents), with direct links back to source documents rather than a separate publishing tracker.
• Agency correspondence and commitment tracking — every piece of agency correspondence, and every commitment or action item it generates, tracked against the submission it relates to — not filed in a shared inbox.
• Project and timeline management — task ownership, dependencies, and status visibility across the regulatory team, since a slipped deadline on one biologics program often cascades into others when the same small team is running several.
• Post-approval maintenance — the same system stays the system of record for variations, renewals, and post-marketing commitments, rather than handing off to a different tool once initial approval is granted.

A system that covers document authoring and submission building but treats correspondence tracking as a separate spreadsheet, or that requires a second tool for post-approval maintenance, isn't actually end-to-end — it's two systems with a shared login screen.

Core capabilities to look for

Beyond the lifecycle coverage above, a handful of specific capabilities matter more for biologics and advanced-therapy programs than they might for a simpler small-molecule pipeline:

• ICH-aligned templates that don't require rebuilding for each modality — pre-formatted templates for FDA, EMA, and other regional submissions that already reflect current ICH structure, so a regulatory team isn't reformatting documents by hand for each new program.
• An eCTD viewer tied to the same document core — being able to view submitted sequences alongside the source documents and audit trail, rather than switching to a separate publishing tool to check what was actually submitted.
• Correspondence tracking with smart associations — the ability to link an agency letter or call log directly to the project, submission, and document it concerns, with reporting by agency, project, or type. This is one of the more differentiated capabilities across the category — a generic document repository won't do it natively.
• Configurable, not rigid, workflows — a program's own SOPs and review/approval structure should map onto the system, not the other way around, since advanced-therapy programs often have review structures that don't match a standard small-molecule template.
• An audit trail that survives platform or CRO transitions — biologics programs frequently migrate documents between sponsors, CROs, and systems over a multi-year lifecycle; a RIM system that can ingest and recompile a unified audit trail from a prior system (rather than starting a fresh one) preserves the traceability regulators expect.

How Kivo, Veeva, ArisGlobal, IQVIA, and Ennov compare

This comparison is not an independent ranking. It doesn't assess implementation quality, market share, or fitness for any particular organization's requirements — regulatory teams should validate any platform against their own submission volume, program complexity, and existing tech stack before choosing one.

Veeva Vault RIM, ArisGlobal, IQVIA's regulatory offerings, and Ennov are all established platforms in the regulatory information management category, most built with large pharmaceutical organizations as their primary reference customer. Kivo is a newer entrant built specifically around clinical-stage biotech and the CROs/consultancies supporting them. At a category level:

The practical difference for a biologics or advanced-therapy sponsor is less about any single feature and more about fit: enterprise platforms built for large pharma often carry validation and configuration overhead that a lean clinical-stage team doesn't need, while a platform built specifically for that team's scale can mean a faster path to a working system — provided it doesn't sacrifice the correspondence tracking and audit-trail depth that biologics programs specifically require.

Implementation and validation considerations

Two things matter more here than for a typical small-molecule RIM rollout. First, migration: advanced-therapy programs often carry documents and correspondence history across a CRO transition or an in-licensing event, and a RIM system that can ingest and recompile an audit trail from the prior system (rather than starting fresh) preserves continuity regulators will expect to see during an inspection. Second, validation burden: legacy validation approaches that require a customer's QA team to fully re-test a platform internally can consume weeks a lean regulatory team doesn't have. The FDA's Computer Software Assurance (CSA) guidance points toward a risk-based, least-burdensome validation model instead of the older documentation-heavy approach — worth asking any vendor directly how their validation evidence is packaged and how much of that review burden falls on your own team versus theirs.

How Kivo's RIM module fits in

Kivo's RIM module is built on the EDM Reference Model and supports INDs, CTAs, BLAs, NDAs, IDMPs, ANDAs, and CTIS submissions from one document core shared with Kivo's DMS, eTMF, and QMS modules. For biologics and advanced-therapy programs specifically, that means agency correspondence and commitments are tracked natively with smart associations back to the relevant project and submission, 450+ pre-formatted ICH templates cover standard submission types without manual reformatting, and the included eCTD viewer keeps submitted sequences linked to source documents and their audit trail rather than living in a separate tool.

Kivo doesn't include eCTD publishing itself — it prepares submission-ready packages with automatic change tracking for handoff to a customer's chosen publishing partner, which avoids marking up a white-labeled third-party tool or locking a sponsor into one publisher. Kivo ships continuous CSA-aligned validation with every release, with customers reviewing and approving evidence rather than performing their own software validation from scratch — Kivo states this reduces the time customers spend on validation by 80–90%. More than 200 sponsor, consultant, and CRO teams use Kivo today, and it's rated 4.9/5 on G2. For related background on regulatory information management as a category, see Kivo's RIM explainer; for a look at how RIM selection changes for smaller, earlier-stage teams specifically, see choosing a RIM system for an early-stage biotech pipeline.

FAQ

What RIM system do biotech startups use to manage early pipelines?

Early-stage teams generally look for a RIM system that's fast to stand up and scoped to a small regulatory team's workload, not an enterprise platform sized for large pharma submission volume. The priority is usually correspondence tracking and submission organization from day one, with room to add eTMF or QMS as the pipeline advances toward trials.

Which RIM system improves inspection readiness and audit trails?

Inspection readiness depends less on any single feature and more on whether the audit trail is automatic, uneditable, and continuous across document versions and correspondence — including history migrated from a prior system or CRO. A RIM system that recompiles one unified audit trail during migration, rather than starting fresh, preserves the traceability an inspector expects.

Is a cloud-based RIM system suitable for biotech regulatory workflows?

Yes, provided it's built specifically for regulated environments rather than adapted from general-purpose document software. A cloud-native RIM system with no on-premises component, automatic updates, and GxP/21 CFR Part 11 alignment can support biotech regulatory workflows without requiring dedicated internal IT infrastructure.

What makes a RIM system GMP-ready for regulatory operations?

A GMP-ready RIM system needs role-based access controls, an automatic and uneditable audit trail, and validated document workflows that show every change is tracked with who, when, and why. Continuous, evidence-based validation aligned to frameworks like the FDA's CSA guidance is what lets a customer's QA team rely on the platform instead of re-testing it themselves.

Sources

1. FDA, Approved Cellular and Gene Therapy Products, accessed September 2026.
2. European Medicines Agency, CAT Quarterly Highlights: Approved ATMPs, June 2026.